KALA BIO
KALA
17 hedge funds and large institutions have $24M invested in KALA BIO in 2024 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 2 closing their positions.
1,195% more capital inflows, than outflows
Capital inflows: $9.18M | Capital outflows: $709K
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
29.13% more ownership
Funds ownership: 45.92% → 75.06% (+29%)
21% more funds holding
Funds holding: 14 → 17 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cormorant Asset Management
Boston,
Massachusetts
|
+$3.8M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$1.96M |
| 3 |
Silverarc Capital Management
Boston,
Massachusetts
|
+$1.46M |
| 4 |
SR One Capital Management
Wayne,
Pennsylvania
|
+$974K |
| 5 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$766K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ADAR1 Capital Management
Austin,
Texas
|
-$539K |
| 2 |
Renaissance Technologies
New York
|
-$122K |
| 3 |
Millennium Management
New York
|
-$28.4K |
| 4 |
Tower Research Capital (TRC)
New York
|
-$9.46K |
| 5 |
Two Sigma Investments
New York
|
-$9.46K |
KALA Hedge Fund Activity: Q4 2024 in Review
17 of the 7,628 institutional investors tracked by Wall St. Rank reported a position in KALA BIO (KALA) for Q4 2024, worth a combined $24M — up 99% from $12.1M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new KALA positions and 2 closed out — a net gain of 3 holders — while 4 added to existing stakes and 3 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $3.8M. The largest seller was ADAR1 Capital Management, cutting an estimated $539K.
- 17 institutional investors held KALA BIO (KALA) as of Q4 2024, up from 14 in Q3 2024.
- Funds reported $24M of KALA BIO stock for Q4 2024, up 99% quarter-over-quarter.
- 5 funds opened new KALA BIO positions in Q4 2024 and 2 closed out, a net change of +3 holders.
- The largest KALA BIO buyer in Q4 2024 was Cormorant Asset Management, an estimated $3.8M added.
- The largest KALA BIO seller in Q4 2024 was ADAR1 Capital Management, an estimated $539K sold.
Based on aggregated 13F filings for Q4 2024.